Note: this article will be updated when new information is available. It’s only been about a month since Brenipatide was christened with its nonproprietary name: before then, it was known as LY3537031. Not a whole lot is known about it, but over the past few days, Lilly has submitted a few trial details that are […]
After an analysis of the current GLP-1 RA research landscape, it’s quite clear that retatrutide’s biggest competition is VK2735. However, it’s fair to say that VK2735 is about equal to retatrutide, and for various reasons, I expect retatrutide to dominate the GLP-1 RA market for quite a few years. A quick primer Although there was […]
Although AusAminos.com is primarily focused on peptides, we’re ultimately agnostic regarding GLP-1 agonist delivery mechanisms. Today, we’re talking about a non-peptide GLP-1 agonist called orforglipron, which is notable for its imminent availability and oral small-molecule mechanism of action, allowing it to be taken as a pill rather than by injection. How does orforglipron compare with […]
You can now buy research ready retatrutide here. This article will be updated as and when new information is made available. So you don’t have to scroll through paragraphs of SEO blog spam, our best estimate for retatrutide availability in Australia is early 2029 for obesity. Drug approval in Australia can take anywhere from 12 […]